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Appendix 2 – Round 2 Questionnaire 
 
PART A (no action necessary) 
 
The following statements achieved consensus: 
 
Statement 1: Cancer registries should routinely collect disease stage data for cases of pediatric cancer. 
 
Statement 2: A primary reason for collecting disease stage in cancer registries is to allow stratified comparison of outcomes between 
groups or over time. 
 
Statement 3: A primary reason for collecting disease stage in cancer registries is to identify trends in late presentation through the 
proxy of advanced stage at diagnosis. 
 
Statement 4: Stage should reflect the extent of disease. 
 
Statement 6: Staging systems used in pediatric cancer registries should be as simple yet informative as possible. 
 
Statement 8: Cancer registries should routinely use pediatric specific staging systems for childhood cancer cases. 
 
Statement 9: For malignancies common in both pediatric and adult populations (e.g. Hodgkin lymphoma, testicular cancer), staging 
systems should be the same across both populations. 
 
Statement 10: Stage should be measured uniformly across all pediatric cancer registries globally to ensure comparability. 
 
Statement 12: When staging pediatric malignancies, clinical staging (i.e. staging at the time of diagnosis) is important and should be 
collected. 
 
Statement 16: Given significant differences in diagnostic capabilities, staging systems appropriate to settings with limited diagnostic 
and evaluation capabilities are needed. 
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Statement 17: Staging systems designed for resource-limited settings with few diagnostic capabilities should be, when possible, based 
on collapsing traditional stages used in resource-rich settings, thus preserving a degree of comparability. 
 
Statement 18: Online tools and/or algorithms which assign stage based on inputted data (e.g. involved sites of disease) are helpful 
when staging pediatric malignancies. 
 
The following statement was eliminated based on ratings and comments: 
 
Statement 5: Stage data in cancer registries do not need to be as detailed as stage data for the purposes of clinical decision making 
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PART B. (ACTION NECESSARY) 
 
The following two statements either did not achieve consensus, were modified based on comments, or both.  Next to each statement 
you will see, the median group score, interquartile range, range, your personal score, and a representative sampling of participant 
comments.  Based on the modifications and the above information, please re-rate the statement.  You may either change your rating or 
leave it the same. 
 
 
 
 
  
Round 1 
Median 
(IQR) 
 
Round 1 
Range 
Your 
Round 
1 
Score 
Representative Comments Strongly 
Agree 
Agree Neither 
Agree nor 
Disagree 
Disagree Strongly 
Disagree 
 
Statement 7 
 
Old statement: 
 
TNM based staging systems used in 
adult patients are of limited use for 
pediatric cases. 
 
Modified statement: 
 
TNM based staging systems used in 
adult patients are of limited use for 
many, but not all pediatric 
malignancies. 
 
 
2 
(1.75-3) 
1-3  
It does not work for all, but it still works for 
some solid tumors and is better than 
nothing. When applicable, TNM can be very 
informative. 
 
Depends entirely on the cancer type, so may 
be perfectly useful for some cancers and 
perfectly useless for others.  Maybe clarify 
“useful for a limited number of pediatric 
cases” to specify the meaning of “limited” 
here? 
 
Depends on the tumour type  
 
For solid tumours, TNM can be used 
 
Not applicable for brain tumors 
1  2  3  4  5  
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Round 1 
Median 
(IQR) 
 
Round 1 
Range 
Your 
Round 
1 
Score 
Representative Comments Strongly 
Agree 
Agree Neither 
Agree nor 
Disagree 
Disagree Strongly 
Disagree 
 
Statement 15 
 
Old statement: 
 
Cancer registries should collect the 
methods of evaluation by which 
stage was determined (e.g. 
diagnostic modalities). 
 
Modified statement: 
 
Ideally, cancer registries should 
collect the methods of evaluation by 
which stage was determined in 
order to assess the adequacy of 
staging (e.g. Chest X-ray vs. CT 
scan for lung metastases). 
 
 
2 
(1-3) 
1-4  
The value of the data is extreme, since US 
diagnosis of abdominal lymph nodes in 
Hodgkin is probably much less sensitive 
than PET-CT scan, so very important to 
know if it is a stage II Hodgkin with US of 
abdomen versus with PET-CT of abdomen. 
In an ideal world yes, but this will be 
resource intensive unless we have 
standardized radiology reporting and more 
automatic data feeds.  
If it could be done well, it may be useful, but 
this has not been my experience. 
In hospital registries, this is possible. But in 
population-based registries, this is difficult 
but certainly can be attempted. 
In the ideal world yes, but depends what 
you are using the data for, I don’t think its 
necessary as it would be rarely used and 
sometimes difficult to find 
It sounds like a laudable goal but one might 
have to collect the evaluation for each 
component rather than just one for stage 
because the information for overall stage 
may be based on multiple methods. 
1  2  3  4  5  
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PART C. (ACTION NECESSARY) 
 
Based on comments, the following one statement was added.  As in the first round, please rate the statement and add any comments 
you feel are important: 
 
 
 Strongl
y 
Agree 
Agree 
Neither Agree nor 
Disagree 
Disagree 
Strongly 
Disagree 
Statemen
t 19 
 
A 
primary 
reason 
for 
collecting 
disease 
stage in 
cancer 
registries 
is 
because 
stage 
may be 
used as a 
proxy for 
treatment
. 
 
 
 
 
 
 
  FORMCHECKBOX    
 
 
  FORMCHECKBOX    
 
 
  FORMCHECKBOX    
 
 
  FORMCHECKBOX    
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Comments on Statement 19 
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PART D. (ACTION NECESSARY) 
 
Based on the comments to statements 13 and 14, two new statements have been added. Below you will find the information for each 
of the original statements, followed by the new statements.  Please rank the new statements: 
 
 
 
  
Round 1 
Median 
(IQR) 
 
Round 1 
Range 
Your 
Round 
1 
Score 
Representative Comments 
 
Statement 13 
 
When staging pediatric 
malignancies, pathologic staging 
(i.e. staging at the time of 
surgery/resection) is important and 
should be collected. 
 
 
 
2 
(1-3) 
1-3  
I am on clear of the value of this in the setting of neoadjuvant chemotherapy. It seems it 
would work and be key for staging the primary tumor and the region when surgery is 
the first step. However, it would not be as useful to evaluate metastatic disease or if 
treatment has been provided. We also need to consider the “staging of the patient” vs. 
“staging of the tumor” as it occurs in retinoblastoma.  
 
The logistics should be taken into account: at which stage is it most feasible for cancer 
registries to collect stage information? Is pathological (or clinical) stage always 
available in the records?  
 
This could applied just for some specific pediatric tumors like Wilm’s tumor, RMS.  
 
For Australian whole-of-population cancer registries, the rule that is applied is that 
stage “at diagnosis” refers to all information available from diagnosis up to 4 months 
post-diagnosis.   Could a similar rule be used for paediatric registries?   
 
With neoadjuvant therapy this may not be applicable to some cases like neuroblastoma 
or germ cell tumor but is very important for response evaluation and prognostication 
in ewings or wilms or rhabdomyosarcoma.  
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Round 1 
Median 
(IQR) 
 
Round 1 
Range 
Your 
Round 
1 
Score 
Representative Comments 
 
Statement 14 
 
Clinical and pathologic staging 
classification systems should be 
identical, and differ only in the time 
point of collection 
 
 
3 
(2-4) 
1-5  
Once again, I am not sure this would be correct because pathologic staging alone 
would not necessarily address distant disease. I believe the correct extent of disease is 
obtained with the information available at diagnosis. If a patient needs to be restaged 
after surgery, then the stage is updated. If surgery occurs upfront, pathologic stage + 
clinical findings will determine local, regional, and metastatic disease extent 
 
Not sure that the time point is the most relevant factor – many possible variations on 
this issue for many cancer types.   
 
They are fundamentally different, apart from timing. 
 
Though the need to keep the staging classification simple, clinical and pathological 
classification need to be different based on the time point and treatment parameters. 
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 Strongl
y 
Agree 
Agree 
Neither Agree nor 
Disagree 
Disagree 
Strongly 
Disagree 
Statement 20 
 
The importance 
of pathologic 
staging (i.e. 
staging at the 
time of 
surgery/resectio
n), and the 
staging system 
by which it 
should be 
collected, will 
vary between 
pediatric 
malignancies. 
 
 
 
 
 
 
  FORMCHECKBOX    
 
 
 FORMCHECKBOX    
 
 
 FORMCHECKBOX    
 
 
 FORMCHECKBOX    
Comments on Statement 20 
 
 
 
 
 
Statement 21 
 
Stage at 
diagnosis, when 
 
 
 
 
 
  FORMCHECKBOX    
 
 
 FORMCHECKBOX    
 
 
 FORMCHECKBOX    
 
 
 FORMCHECKBOX    
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collected, should 
incorporate all 
information 
available from 
diagnosis to 4 
months post 
diagnosis. 
 
Comments on Statement 21 
 
 
 
 
 
 
